Evaxion A/S (EVAX) Expected to Post Earnings on Thursday

Evaxion A/S (NASDAQ:EVAX) is expected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Evaxion A/S to post earnings of ($0.01) per share and revenue of $6.70 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.

Evaxion A/S Stock Up 0.3%

Shares of NASDAQ EVAX opened at $3.06 on Wednesday. Evaxion A/S has a 12-month low of $2.52 and a 12-month high of $12.15. The firm’s 50-day simple moving average is $3.20 and its 200 day simple moving average is $3.58. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. The company has a market cap of $25.52 million, a price-to-earnings ratio of -2.08 and a beta of 0.29.

Hedge Funds Weigh In On Evaxion A/S

An institutional investor recently bought a new position in Evaxion A/S stock. SmartHarvest Portfolios LLC acquired a new position in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 15,194 shares of the company’s stock, valued at approximately $72,000. SmartHarvest Portfolios LLC owned about 0.18% of Evaxion A/S at the end of the most recent quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Evaxion A/S in a research note on Friday, April 24th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.